AstraZeneca, Pozen Sue Lupin To Block Generic Vimovo
In addition to AstraZeneca and Pozen, which co-developed Vimovo, the suit includes as plaintiffs AstraZeneca LP and KBI-E Inc., which is an exclusive licensee of five of the six patents-in-suit. Sweden-based AstraZeneca owns those five patents by assignment, while Pozen owns the sixth, according to the complaint.
The submission of an abbreviated new drug application seeking U.S. Food and...
To view the full article, register now.